Document is current
Any future updates will be listed below
-
Authors
Jongbloed, Elisabeth M.
Wortelboer, Noor https://orcid.org/0009-0006-1649-748X
de Weerd, Vanja
Beaufort, Corine M.
Ruigrok-Ritstier, Kirsten
Van, Mai N.
Kraan, Jaco https://orcid.org/0000-0001-7445-7984
van Zweeden, Annette A.
van der Padt-Pruijsten, Annemieke
Hamming, Lisanne C.
Konings, Inge R.
Sonke, Gabe S. https://orcid.org/0000-0001-8088-9628
Oomen-de Hoop, Esther https://orcid.org/0000-0003-2506-3852
Martens, John W. M. https://orcid.org/0000-0002-3428-3366
Jager, Agnes https://orcid.org/0000-0002-7713-1450
Wilting, Saskia M. https://orcid.org/0000-0002-2838-841X
-
Funding
Funding for this research was provided by:
Breast Cancer Now (2018NovPCC100)
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 25 July 2025
First Online: 4 September 2025
Competing interests
: Institutional research grant support was received from the following: Novartis (I.R.K. and G.S.S.); Gilead (I.R.K.); Agendia and AstraZeneca (G.S.S. and A.J.); Merck (G.S.S. and J.W.M.M.); Roche and Seasgen (G.S.S.); Bayer, Menarini and Tzu Genomics (J.W.M.M.) and Pfizer (A.J. and S.M.W.). Consultancy was received from Biovica, Novaratis and Seagen (G.S.S.) and Novartis (J.W.M.M.). Participation on the advisory board of AstraZeneca (A.J.). The other authors declare no competing interests.
